

Kura Mynis: Preclinical Safety Data

Acute oral toxicity and in vitro cell viability — the measured results, in full.

About this document. A summary prepared by Bykare Sdn Bhd, reproducing the safety measurements recorded in a preclinical evaluation carried out by the School of Pharmacy, Lincoln University College (Wisma Lincoln, SS 6/12, 47301 Selangor, Malaysia), reported in January 2026. **Kura Mynis is a food supplement, not a medicine, and is not intended to diagnose, treat, cure or prevent any disease.**

01 — ACUTE ORAL TOXICITY

A single dose far above any normal serving

Conducted under **OECD Test Guideline 423**, the international protocol that allows results from different laboratories to be compared. Kura Mynis was administered as a single oral dose of **6,000 mg per kg of body weight** to three adult female Wistar rats (200–350 g). The animals were observed continuously for the first two hours, then daily for fourteen days.

Measure	Result over 14 days
Mortality	None
Signs of toxicity	None observed
Behavioural / somatomotor changes	None observed
Body weight at start	208.43 ± 19.30 g
Body weight at day 14	215.10 ± 21.82 g
Change in body weight	+6.67 ± 0.94 g — normal gradual gain

6,000 mg/kg is the upper limit dose for this class of test; the protocol does not routinely go higher.

Twelve observational parameters were recorded for each animal at two hours, day one and day fourteen. Every one was normal or absent at every timepoint:

Fur and skin	Normal	Diarrhoea	Absent
Eyes (exophthalmos, lacrimation)	Normal	Sleep	Normal
Salivation	Absent	Itching	Absent
Respiration	Normal	Motor activity	Normal
Urination	Normal	Grip strength	Normal
Faeces consistency	Normal	Convulsion / tremor / coma	Absent

02 — IN VITRO CELL VIABILITY

What happened to human liver cells

An **MTT assay** measures how many cells remain alive and metabolically active after treatment: living cells convert a yellow dye into purple crystals, and the intensity is read at 570 nm. The cells were **Hep-G2**, a human liver cell line, tested over 24 hours. Liver cells are the appropriate model because the liver processes everything that is

swallowed.

Concentration	Cell viability after 24 h
Untreated control	100% (reference)
20 µg/ml	100.25%
40 µg/ml	99.96%
60 µg/ml	94.61%
80 µg/ml	92.66%
100 µg/ml	91.66%

Linear fit $y = -0.1224x + 103.17$, $R^2 = 0.9145$. **IC50 was not reached** within the tested range.

More than nine in ten cells were still alive at the highest concentration tested, and the concentration that would kill half the cells was never reached. In a cytotoxicity screen, that is the intended result: the formulation did not behave as a cell poison.

One clarification. Hep-G2 is derived from a liver cancer and is used worldwide as the standard laboratory stand-in for human liver cells. Its use here says **nothing whatsoever about cancer**, in either direction. It was chosen because it is the conventional model for liver-cell testing.

03 — SCOPE

What this testing covers

Between them, the two tests establish something specific: at the doses examined, the formulation showed no acute toxicity, and it was not cytotoxic to human liver cells. Both were carried out in the laboratory — a cell-based assay and an animal safety protocol, each run under a standard published method.

- **A food supplement, not a medicine.** Kura Mynis is not a treatment for any condition and is not a substitute for prescribed medication.

Before you take it. If you take any medication for blood sugar, speak to your doctor or pharmacist before adding this or any supplement — the risk being managed is blood sugar going too low. The same applies if you are pregnant or breastfeeding, take prescription medication of any kind, have a diagnosed liver or kidney condition, or have a seafood or shellfish allergy (the formulation contains brown seaweed). Kura Mynis is formulated for adults.

This document is for general information and is not medical advice. Individual results vary. Bykare Sdn Bhd · bykare.com · Source: School of Pharmacy, Lincoln University College, January 2026.